DermTech, Inc.
DelistedCIK 1651944fmd_0JRCWMBQC954T147CS0SQV3EP9Services · Services-Medical LaboratoriesTemplate: Standard
Coverage: Jan 02, 2016 to Mar 31, 2024, 32 periods
| Line item | FY2017 | FY2018 | FY2018 | FY2019 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | 2 | – | 3 | 6 | 12 | 15 | 15 |
| Cost of revenue | – | – | 3 | – | 3 | 6 | 11 | 14 | 15 |
| Net interest income | – | – | – | 0 | – | – | – | – | – |
| Commissions and fees | – | 0 | – | – | – | – | – | – | – |
| Gross profit | – | – | (0) | – | 0 | (0) | 1 | 1 | 0 |
| Research and development | – | – | 2 | – | 2 | 5 | 16 | 24 | 15 |
| Selling, general and administrative | – | – | 6 | – | 15 | 30 | 62 | 95 | 89 |
| Total operating expenses | 0 | 0 | – | – | 18 | 35 | 79 | 119 | 104 |
| Operating income | (0) | (0) | – | – | (18) | (35) | (77) | (118) | (104) |
| Interest and investment income | 0 | 1 | – | 3 | – | – | – | – | – |
| Other non-operating income (expense) | – | – | (1) | – | (3) | (1) | (1) | 1 | 3 |
| Net income | (0) | – | (10) | – | (20) | (36) | (78) | (117) | (101) |
| Net income to common shareholders | (0) | (0) | – | 1 | – | – | – | – | – |